Gyre Therapeutics (GYRE) Net Cash Flow (2016 - 2025)
Historic Net Cash Flow for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $3.8 million.
- Gyre Therapeutics' Net Cash Flow rose 121364.99% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 96201.38%. This contributed to the annual value of -$21.4 million for FY2024, which is 34818.12% down from last year.
- As of Q3 2025, Gyre Therapeutics' Net Cash Flow stood at $3.8 million, which was up 121364.99% from $21.4 million recorded in Q2 2025.
- Over the past 5 years, Gyre Therapeutics' Net Cash Flow peaked at $52.7 million during Q1 2021, and registered a low of -$52.3 million during Q3 2022.
- In the last 5 years, Gyre Therapeutics' Net Cash Flow had a median value of -$3.8 million in 2024 and averaged -$977842.1.
- Per our database at Business Quant, Gyre Therapeutics' Net Cash Flow crashed by 37239.29% in 2021 and then soared by 121364.99% in 2025.
- Gyre Therapeutics' Net Cash Flow (Quarter) stood at -$14.8 million in 2021, then tumbled by 81.57% to -$26.9 million in 2022, then skyrocketed by 174.15% to $19.9 million in 2023, then tumbled by 119.05% to -$3.8 million in 2024, then soared by 198.82% to $3.8 million in 2025.
- Its Net Cash Flow was $3.8 million in Q3 2025, compared to $21.4 million in Q2 2025 and $3.2 million in Q1 2025.